TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31729108

Group type: EXPERIMENTAL
Intervention: Magnolol additive (MA) at 100, 200, and 300 mg/kg for 3 weeks
Number of subjects: 275

Group type: COMPARATOR
Intervention: Colistin sulphate (CS) at 30 mg/kg for 3 weeks
Number of subjects: 275
Study: 29898827

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 666

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 666
Study: 28379873

Group type: EXPERIMENTAL
Intervention: Internet-delivered positive psychology program
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive-behavioral program
Number of subjects: 276

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 276
Study: 26246481

Group type: EXPERIMENTAL
Intervention: Intensive follow-up including physical examination, bone scintigraphy, chest CT, abdominal CT, brain MRI/CT, and frequent tumor marker evaluations.
Number of subjects: 1700

Group type: COMPARATOR
Intervention: Standard follow-up including physical examination at the same frequency and tumor markers evaluated once a year.
Number of subjects: 1700
Study: 23908141

Group type: EXPERIMENTAL
Intervention: MCPH1-2550-CC genotype with 10-27 pack-years of smoking
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: MCPH1-2550-TC genotype with >27 pack-years of smoking
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: TopBP1-3257 A allele in current smokers
Number of subjects: 1348
Study: 21918956

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (two cycles of cisplatin and 5-fluorouracil)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Postoperative chemotherapy (two cycles of cisplatin and 5-fluorouracil)
Number of subjects: 330
Study: 19322976

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary percutaneous intervention (PCI) for ST
Number of subjects: 0
Study: 16700031

Group type: EXPERIMENTAL
Intervention: Tendon vibration applied to the wrist extensor muscles
Number of subjects: 3
Study: 14570671

Group type: EXPERIMENTAL
Intervention: Silicone tracheal tube
Number of subjects: 80
Study: 12598249

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 0
Study: 10507591

Group type: EXPERIMENTAL
Intervention: Intravenous antihistamines (diphenhydramine, 1 mg/kg, and cimetidine, 4 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8942464

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 46

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 46
Study: 1925417

Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 41
Study: 6642386

Group type: EXPERIMENTAL
Intervention: Alizapride
Number of subjects: 40

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 40
Study: 4028748

Group type: EXPERIMENTAL
Intervention: 3 mg/kg of dipyridamole for 24 hours
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups received 100 mg of aspirin daily
Number of subjects: 40
Study: 30044302

Group type: EXPERIMENTAL
Intervention: NNRTI (efavirenz or nevirapine)
Number of subjects: 400

Group type: COMPARATOR
Intervention: PI (lopinavir/ritonavir)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: NNRTI
Number of subjects: 400

Group type: COMPARATOR
Intervention: PI
Number of subjects: 400
Study: 28176386

Group type: EXPERIMENTAL
Intervention: Intensive bisphosphonate therapy (zoledronic acid)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 502
Study: 26262251

Group type: EXPERIMENTAL
Intervention: Highly specific reminders (to monitor K+) and alerts (of hyperkalaemia)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reminders and alerts suppressed
Number of subjects: 0
Study: 23538648

Group type: EXPERIMENTAL
Intervention: Nutritional status measured by Mini Nutritional Assessment (MNA)
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Type of dementia
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Advanced age and worse cognitive, functional and behavioural profile
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Behavioural symptoms (NPI-Q)
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Dependence in any basic or instrumental ADL
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Feeding dependence
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Food preparation dependence
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Logistic regression model for at risk/malnutrition
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Logistic regression model for malnutrition
Number of subjects: 940
Study: 21147262

Group type: EXPERIMENTAL
Intervention: Fish oil (6 g/day for ≥1 month)
Number of subjects: 61
Study: 18279500

Group type: EXPERIMENTAL
Intervention: Five-point scale version of the Norwegian Function Assessment Scale (NFAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Four-point scale version of the Norwegian Function Assessment Scale (NFAS)
Number of subjects: 0
Study: 16545510

Group type: EXPERIMENTAL
Intervention: PCECV
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: PVRV
Number of subjects: 180

Group type: COMPARATOR
Intervention: PCECV or PVRV
Number of subjects: 180
Study: 12601676

Group type: EXPERIMENTAL
Intervention: Single-dose administration of Hypericum extract LI 160 (6 or 12 coated tablets, 5400 or 10800 microgram hypericin)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Steady-state administration of Hypericum extract LI 160 (initial dose of 6 tablets, 5400 microgram hypericin, followed by 3 x 1 tablets, 2700 microgram hypericin per day for 7 days)
Number of subjects: 72
Study: 10831141

Group type: EXPERIMENTAL
Intervention: Adolescents responding quickly to scenarios
Number of subjects: 55

Group type: COMPARATOR
Intervention: Mothers interpreting scenarios
Number of subjects: 55
Study: 9122747

Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT) followed by autologous bone marrow transplantation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 200
Study: 8447211

Group type: EXPERIMENTAL
Intervention: Oesophageal rewarmer (OeR group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (without oesophageal rewarmer)
Number of subjects: 20
Study: 3462423

Group type: EXPERIMENTAL
Intervention: Continuous Ambulatory Peritoneal Dialysis (CAPD)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Chronic Hemodialysis
Number of subjects: 76
Study: 29940536

Group type: EXPERIMENTAL
Intervention: Acceptance-based techniques
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control-based techniques
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 151
Study: 26313157

Group type: EXPERIMENTAL
Intervention: MNTX-ER (500 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: MNTX-SC (12 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: MNTX-IR (500 mg)
Number of subjects: 15
Study: 24980265

Group type: EXPERIMENTAL
Intervention: Live saxophone music therapy (30 minutes)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (no music therapy)
Number of subjects: 114
Study: 22633316

Group type: COMPARATOR
Intervention: Posturographic parameters (static and dynamic tests)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Limits of stability test
Number of subjects: 89

Group type: COMPARATOR
Intervention: Rhythmic weight shift tests
Number of subjects: 89
Study: 19789440

Group type: EXPERIMENTAL
Intervention: Continuous lateral rotation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 0
Study: 17999977

Group type: EXPERIMENTAL
Intervention: Atazanavir (49 on 400 mg once daily, and 53 on 300 mg plus 100 mg of ritonavir once daily)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir
Number of subjects: 189
Study: 16642175

Group type: EXPERIMENTAL
Intervention: Normal integration of local motion direction signals in amblyopia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous studies on global motion processing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous studies on signal integration
Number of subjects: 0
Study: 14662267

Group type: EXPERIMENTAL
Intervention: Thrombectomy with the X-SIZER device
Number of subjects: 797

Group type: COMPARATOR
Intervention: Control (no thrombectomy)
Number of subjects: 797
Study: 10716102

Group type: EXPERIMENTAL
Intervention: Clonidine only (5 days)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Clonidine, oxazepam, baclofen, and ketoprofene with naloxone and naltrexone (2 days)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Methadone in decreasing doses (10 days)
Number of subjects: 98
Study: 9213861

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg/12 hourly)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms/12 hourly)
Number of subjects: 20
Study: 1528502

Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 2996747

Group type: EXPERIMENTAL
Intervention: Intensive chemo‐radio‐immunotherapy regimen with cyclophosphamide, doxorubicin, vincristine, VP‐16, and cisplatin, followed by prophylactic whole‐brain radiotherapy and multifield radiotherapy.
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Thymosin, fraction V (experimental group).
Number of subjects: 35

Group type: COMPARATOR
Intervention: No thymosin (control group).
Number of subjects: 35
Study: 31605550

Group type: EXPERIMENTAL
Intervention: M. bovoculi vaccine (2 doses)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Control (unvaccinated)
Number of subjects: 370
Study: 29411765

Group type: EXPERIMENTAL
Intervention: aceclofenac + pregabalin
Number of subjects: 60

Group type: COMPARATOR
Intervention: aceclofenac
Number of subjects: 60
Study: 25719429

Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride (1500 mg/d) plus chondroitin sulfate (1200 mg/d) for 28 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 23011351

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 21345843

Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (TAT, DAT plus cilostazol)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (TAT) in carriers of CYP2C19 LOF allele
Number of subjects: 474

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAT) in carriers of CYP2C19 LOF allele
Number of subjects: 474

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAT) in non-carriers of CYP2C19 LOF allele
Number of subjects: 474
Study: 18197184

Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Exercise (HIIE)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Steady-State Exercise (SSE)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (CONT)
Number of subjects: 45
Study: 16484290

Group type: EXPERIMENTAL
Intervention: Iloprost treatment (intravenous infusion at progressively increasing doses from 0.5 to 2 ng/kg/min for 6 hours each day for 10 days, repeated every 3 months for 18 months)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Iloprost treatment (new protocol)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Iloprost treatment (different dosing schemes)
Number of subjects: 30
Study: 12930167

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.3 g.kg body mass per day for 6 days)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 15
Study: 10735426

Group type: EXPERIMENTAL
Intervention: External beam irradiation (7 Gy at 0-24 hours and 24-48 hours after intervention)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Angioplasty and/or stent placement alone (control group)
Number of subjects: 31
Study: 8884833

Group type: EXPERIMENTAL
Intervention: Hanks balanced salt solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Custodiol solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sterile saline solution
Number of subjects: 0
Study: 1326734

Group type: EXPERIMENTAL
Intervention: High-dose 4'-epi-doxorubicin + cyclophosphamide (800 mg/m2)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: High-dose 4'-epi-doxorubicin + cisplatin (60 mg/m2)
Number of subjects: 111
Study: 3915883

Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg once daily for 15 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Piroxicam 20 mg once daily for 15 days
Number of subjects: 100
Study: 31820603

Group type: EXPERIMENTAL
Intervention: Acupuncture at Qianlianquan (Extra) and eight confluent points (Neiguan (PC 6), Waiguan (TE 5), Lieque (LU 7), Houxi (SI 3), Gongsun (SP 4), Shenmai (BL 62), Zhaohai (KI 6), Zulinqi (GB 41)), once a day, 6 days as one course, 4 courses total
Number of subjects: 42

Group type: COMPARATOR
Intervention: Qinghou Liyan granules, 5 g each time, 3 times a day, 7 days as one course, 4 courses total
Number of subjects: 42
Study: 30361170

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 945

Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 945
Study: 26945407

Group type: EXPERIMENTAL
Intervention: 1-hour infusion of recombinant human atrial natriuretic peptide (rhANP)
Number of subjects: 477

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study: 24091995

Group type: EXPERIMENTAL
Intervention: Overload training (n = 18)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control training (CTL, n = 9)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Overload training (F-OR, n = 9)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Overload training (AF, n = 9)
Number of subjects: 27
Study: 22197455

Group type: EXPERIMENTAL
Intervention: Citrus-based juice (300 mL daily for 6 months)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo beverage (300 mL daily for 6 months)
Number of subjects: 33
Study: 20711715

Group type: EXPERIMENTAL
Intervention: Insulin pump treatment with continuous glucose monitoring
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional self‐monitoring blood glucose measurements (Control)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sensor-treated 12‐ to 16‐year‐old patients
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group without sensors
Number of subjects: 160
Study: 17543505

Group type: EXPERIMENTAL
Intervention: Olanzapine (n=120)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Risperidone (n=115)
Number of subjects: 235
Study: 15199625

Group type: EXPERIMENTAL
Intervention: Jieyu pill (JYP)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Maprotiline (Map)
Number of subjects: 57
Study: 12173815

Group type: EXPERIMENTAL
Intervention: Leukodepletion (group B: n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonpulsatile CPB without leukodepletion (group A: n = 20)
Number of subjects: 40
Study: 9814931

Group type: EXPERIMENTAL
Intervention: Low-energy density shock wave therapy (1500 impulses of 0.06 mJ/mm2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High-energy density shock wave therapy (1500 impulses of 0.28 mJ/mm2)
Number of subjects: 100
Study: 9027784

Group type: EXPERIMENTAL
Intervention: Haemodialysis with cuprophane membranes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Haemodialysis with polysulphone membranes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Haemodialysis patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Haemodialysis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study: 1843987

Group type: EXPERIMENTAL
Intervention: Ferric sulfate (FS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Formocresol (FC)
Number of subjects: 62
Study: 6177167

Group type: EXPERIMENTAL
Intervention: Budesonide 0.025% (Preferid)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hydrocortisone‐17‐butyrate 0.1% (Locoid)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Betamethasone‐17,21‐dipropionate 0.5% (Diproderm)
Number of subjects: 9
Study: 31352497

Group type: EXPERIMENTAL
Intervention: Robot-assisted total knee arthroplasty (rTKA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional measured resection total knee arthroplasty (sTKA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both rTKA and sTKA
Number of subjects: 10
Study: 30611296

Group type: EXPERIMENTAL
Intervention: Concomitant salpingectomy
Number of subjects: 2800

Group type: COMPARATOR
Intervention: No salpingectomy
Number of subjects: 2800
Study: 28729302

Group type: EXPERIMENTAL
Intervention: Vosaroxin 70 mg/m2 on days 1 and 4 with decitabine 20 mg/m2 on days 1-5 every 4-6 weeks for up to seven cycles
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Vosaroxin 70 mg/m2
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Minimal residual disease-negative status by multiparametric flow-cytometry at response (± 3 months)
Number of subjects: 65
Study: 23688877

Group type: EXPERIMENTAL
Intervention: Acrysof SN6AT IOL (Group A)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: AT Torbi 709M IOL (Group B)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Both Groups
Number of subjects: 72
Study: 21843688

Group type: EXPERIMENTAL
Intervention: Immediate insertion (within 10 min of placenta delivery)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Early insertion (10 min to 48 h postpartum)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Interval insertion (≥6 weeks postpartum)
Number of subjects: 46
Study: 19250118

Group type: EXPERIMENTAL
Intervention: Central sleep apnea (CSA)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA)
Number of subjects: 129

Group type: COMPARATOR
Intervention: No sleep apnea
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Comparison of CSA and OSA
Number of subjects: 129
Study: 17259188

Group type: EXPERIMENTAL
Intervention: Rapid diagnostic test (RDT)
Number of subjects: 2416

Group type: COMPARATOR
Intervention: Routine microscopy
Number of subjects: 2416

Group type: EXPERIMENTAL
Intervention: Negative test by any method
Number of subjects: 2416

Group type: EXPERIMENTAL
Intervention: Children aged under 5 with negative rapid diagnostic tests
Number of subjects: 2416
Study: 15493565

Group type: EXPERIMENTAL
Intervention: recombinant human follicle-stimulating hormone (rFSH)
Number of subjects: 241

Group type: COMPARATOR
Intervention: highly purified urinary human FSH (uFSH)
Number of subjects: 241
Study: 11406840

Group type: EXPERIMENTAL
Intervention: Proposed test for overall treatment effect
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commonly used tests in fixed effects model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commonly used tests in random effects model
Number of subjects: 0
Study: 9255748

Group type: EXPERIMENTAL
Intervention: Oral micronized 17 beta‐estradiol/oral sequential dydrogesterone
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta‐estradiol/oral sequential dydrogesterone
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Oral tibolone
Number of subjects: 85

Group type: COMPARATOR
Intervention: No hormone replacement therapy
Number of subjects: 85
Study: 8291388

Group type: EXPERIMENTAL
Intervention: Titrated sufentanil-midazolam infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard postoperative analgesia with intravenous increments of morphine and midazolam
Number of subjects: 20
Study: 2872429

Group type: EXPERIMENTAL
Intervention: Intravenous ritodrine hydrochloride
Number of subjects: 106

Group type: COMPARATOR
Intervention: No tocolytic treatment (Control)
Number of subjects: 106
Study: 30192782

Group type: EXPERIMENTAL
Intervention: GR-MD-02 (8 mg.kg-1 via IV infusion, biweekly for 16 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 27100898

Group type: EXPERIMENTAL
Intervention: Low-dose alcohol (0.02 g/100 ml blood alcohol concentration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (alcohol-free, wine-flavored beverage)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (informed about non-alcoholic beverage)
Number of subjects: 0
Study: 24583546

Group type: EXPERIMENTAL
Intervention: Upright locomotion replacement training (LRT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Quiet upright standing (STA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 10
Study: 22437449

Group type: COMPARATOR
Intervention: Lacosamide 50 mg single dose
Number of subjects: 48

Group type: COMPARATOR
Intervention: Lacosamide 100 mg twice daily
Number of subjects: 48

Group type: COMPARATOR
Intervention: Lacosamide 200 mg twice daily
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 20464647

Group type: EXPERIMENTAL
Intervention: Ipratropium (80 microg) in the morning
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo in the morning
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ipratropium (80 microg) in the evening
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo in the evening
Number of subjects: 21
Study: 18367682

Group type: EXPERIMENTAL
Intervention: Voice Production Therapy (VP)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Vocal Hygiene Education (VHE)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Voice Production Therapy (VP) with self-study
Number of subjects: 62

Group type: COMPARATOR
Intervention: Vocal Hygiene Education (VHE) with self-study
Number of subjects: 62
Study: 15726579

Group type: EXPERIMENTAL
Intervention: Piribedil (2-16 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Piribedil (16 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 12457375

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 71

Group type: COMPARATOR
Intervention: Moclobemide
Number of subjects: 71
Study: 10517737

Group type: EXPERIMENTAL
Intervention: Angiotensin II (Ang II) infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Candesartan (inhibitor of Ang II AT1 receptor)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Losartan (50 mg UID)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Atenolol (50 mg UID)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20